Group items tagged

Applicants must choose one of the following categories they feel their project best exemplifies: 1.) Outstanding Emerging Innovation: The winning nominee is a person or company working on the basic research phase of an innovation - for three years or less, pre-commercialization - that has received grant money or outside money and that demonstrates the potential for continued growth and success. 2.) Outstanding Bioscience Innovation: The winning nominee is a company that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenetics. 3.) Outstanding Information Technology Innovation: The winning nominee is a company that has achieved a significant milestone in information technology, including hardware and software, packaged applications, custom applications and digital media. 4.) Outstanding Marketing Innovation: The winning nominee is a company that has achieved a significant milestone in consumer marketing. 5.) Outstanding Advanced Engineering Innovation: The winning nominee is a company that has achieved a significant milestone in advanced engineering - where technology is used to design a product.

The following programs have due dates that fall between October 1 - 25, 2013, and these dates are being revised due to the Federal  government shutdown. These revised dates apply whether the proposal is being submitted via the NSF FastLane System or  Grants.gov. Due to compressed proposal deadlines resulting from the shutdown, proposers are advised that they may experience a  delay when contacting IT Help Central with technical support questions. Frequently asked questions regarding these date changes  are available on the Resumption of Operations page on the NSF website at: http://www.nsf.gov/bfa/dias/policy/postshutdown.jsp. 

The Bill & Melinda Gates Foundation is accepting applications for Round 14 of its Grand Challenges Explorations initiative, an accelerated grant program that encourages bold approaches aimed at improving the lives of the world's poorest people. Anyone - students, scientists, entrepreneurs - with a transformative idea is invited to apply.

This challenge focuses on innovations in vaccine manufacturing platforms designed to lower production cost for vaccines that target diseases of great global burden and that are among the most costly to produce with current technologies. The vaccines should target one of the following diseases: human papillomavirus vaccine; inactivated poliovirus vaccine; measles-rubella vaccine; pentavalent vaccine (diphtheria, tetanus, whole-cell pertussis, hepatitis B, Hib); pneumococcal vaccine; or rotavirus vaccine. The target production cost of ≤ $0.15 per dose should represent the fully-loaded cost, which ensures that all relevant costs are accounted for.